摘要:
The presented invention is related to a vaccine, a pharmaceutical composition, a carrier for nucleic acids and for other biologically active substances, use of composition in vaccine manufacturing and use of cationic derivatives of PTAI in production of immunomodulating substances. More specifically, the presented invention is related to use of carriers based on cationic derivatives of polyprenols used as DNA vaccine carriers, easily transported and stored.
摘要:
An exemplary embodiment relates to a method of using a plant-derived miR172 molecule or its synthetic equivalent, selected from amongst miR172a or miR172b, for decreasing inflammatory processes in an organism, a method of decreasing B and T lymphocyte proliferation, as well as a method of reducing protein FAN (Factor Associated with Neutral Sphingomyelinase Activation) level. Exemplary embodiments provide a novel therapeutic method based on miRNA molecules, which through the interaction with mRNA encoding FAN protein, negatively regulate its expression and decrease the inflammatory response of the organism.
摘要:
The present invention provides the means and the methods for obtaining plant materials producing large amounts of functionally active cysteine synthase (EC 2.5.1.47) that rely on an environment-friendly and health-safe enzyme production process for synthesis of L-cysteine and L-cystine, therefore suitably accounting among the c-GMP standards for production of the aforementioned compounds, namely of non-human and non-animal origin. Described is a recombinant DNA molecule comprising a nucleic acid molecule encoding a protein having cysteine synthase activity, wherein the said nucleic acid molecule is operably linked to regulatory elements allowing the expression of the nucleic acid molecule in plant cells. The present invention also provides a vector harboring the plant expression cassette comprising the said recombinant DNA molecule, as well as plant cells, plant tissues and plants transformed therewith. The present invention further describes the use of the aforementioned recombinant DNA molecule and vector in plant cell culture, plant tissue culture, and plant breeding; further presented are examples of the use of the said plant cells, plant tissues, plants, as well as the extracts from these plant raw materials for biosynthetic production of L-cysteine and/or L-cystine compounds being valuables in a broad range of applications, such as for production of additives or ingredients used in agroindustrial, cosmetic and pharmaceutic processes.
摘要:
The invention is related to a factor increasing efficiency of a DNA vaccine aimed against a virus, a plasmid DNA preparation, a DNA vaccine, a method of obtaining a modified 3NFKB expression vector and use of a nucleotide sequence recognised by NFKB. More particularly, the provided solution is related to use of a DNA sequence recognised by the NF kappa B nuclear transcription factor (NFKB,nuclear factor kappa B) in a vaccine in order to ensure effective vaccine plasmid transport into the nucleus and to enhance transcription levels of the introduced gene-coding a selected antigen.
摘要:
4'-Ethynylostavudine derivatives according to the invention substituted at 4'-ethynylostavudine 5'-O-position with 12-tetradodecanoyl, 12-bromododecanoyl, 12-methoxydodecanoyl, 12-ethylothiododecanoyl, or 12-azidododecanoyl group (represented by the symbols WA37, WA38, WA40, WA42, WA39 ) in deClPhR™ cells exert very high antiviral activity against the wild type HIV-1 strain, as well as against its drug and multidrug resistant strains, without any citotoxicty at the therapeutic concentrations (CC 50 >200 µM). These compounds, because of their very low toxicity may be applied at all phases of AIDS, even at the final phase when the T4 lymphocytes level in patients drops down below 200/µL of peripheral blood. The 2',3'- didehydro-3'-deoxy-4'-ethynylothymidine derivatives, according to the invention, are synthesized by the transformation of the known compound 4'-ethynylostavudine ( WA32, wherein R represents hydrogen).
摘要:
The subject of the invention is an influenza virus haemagglutinin antigen, an influenza vaccine comprising said antigen, a method of producing said antigen, and use of the antigen as stated above to produce an influenza vaccine. The invention involves a new method of producing said antigen, suitable for use in a vaccine. The outcome as stated in the invention leads to obtaining a highly immunogenic antigen, which does not require contact with the whole virus but just haemagglutinin. The vaccine as described in the invention does not contain the virus or its parts, does not contain cells coming from other organisms or their parts, but only purified haemagglutinin antigen.